Welcome to our dedicated page for Heron Therapeutics news (Ticker: HRTX), a resource for investors and traders seeking the latest updates and insights on Heron Therapeutics stock.
Heron Therapeutics, Inc. (Nasdaq: HRTX) is a leading commercial-stage biotechnology company focused on enhancing patient care through the development and commercialization of innovative therapeutic solutions. Specializing in the use of its proprietary Biochronomer™ polymer-based drug delivery platform, Heron is revolutionizing the pharmaceutical landscape by converting daily injectable drugs into weekly or bi-weekly regimens.
The company's product portfolio includes APONVIE, SUSTOL, ZYNRELEF, and CINVANTI, which target unmet medical needs in both acute care and oncology settings. APONVIE is effective in preventing postoperative nausea and vomiting, offering a quick 30-second IV push that is bioequivalent to oral aprepitant. SUSTOL utilizes Heron's Biochronomer® technology to extend therapeutic levels of granisetron for over five days, aiding in the prevention of chemotherapy-induced nausea and vomiting (CINV).
ZYNRELEF, a dual-acting local anesthetic combining bupivacaine and meloxicam, is notably the first extended-release local anesthetic demonstrating superior pain management and reducing opioid use for up to 72 hours post-surgery. Originally approved by the FDA in May 2021, its indication was expanded in January 2024 to cover various soft tissue and orthopedic surgeries. Recently, Heron submitted a Prior Approval Supplement (PAS) for a Vial Access Needle to streamline ZYNRELEF's preparation process, potentially enhancing its adoption in clinical settings.
CINVANTI, an IV formulation of aprepitant, significantly reduces both acute and delayed phases of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy, improving overall patient quality of life during treatment.
Financially, Heron Therapeutics is on a robust trajectory, having implemented a cost reduction program projected to save approximately $75 million through 2025. The company has secured $30 million in equity financing and a $50 million working capital facility, aiming to achieve profitability with its current operational strategies.
Heron’s strong focus on clinical excellence and strategic partnerships, such as its recent collaboration with CrossLink Life Sciences to expand ZYNRELEF's sales network, underscores its commitment to delivering substantial value and improving patient outcomes. For more detailed information, visit herontx.com.
Heron Therapeutics reported Q3 2021 financial results, with net product sales of $23.2 million, a rise from $20.0 million in Q3 2020. The company achieved $65.7 million in net sales for the nine months ended September 30, 2021, compared to $68.0 million the prior year. ZYNRELEF, launched July 2021, generated $2.1 million in sales, with strong formulary approvals. Despite a net loss of $52.4 million for Q3 2021, down from $58.2 million in Q3 2020, cash reserves were $202.8 million as of September 30, 2021. Future guidance suggests moderated cash usage and potential sales growth in 2022.
Heron Therapeutics (Nasdaq: HRTX) will host a conference call on November 3, 2021, at 4:15 p.m. ET to discuss their third quarter 2021 financial results and recent business highlights. The call is accessible via phone for domestic and international callers and will also be available as a webcast on Heron's website. An archive will be provided for 60 days. Heron focuses on developing innovative treatments to meet unmet patient needs in acute care and oncology.
Heron Therapeutics, Inc. (Nasdaq: HRTX) submitted a supplemental New Drug Application (NDA) to the FDA for its product ZYNRELEF, expanding its indication to include foot and ankle, small-to-medium open abdominal, and lower extremity joint surgeries without the need for additional studies. This followed a successful Type C meeting with the FDA, which allows for two sequential NDA submissions. The company aims to significantly increase the number of indicated procedures, targeting up to 14 million surgeries. ZYNRELEF is the first extended-release local anesthetic approved for postoperative pain management.
Heron Therapeutics, Inc. (Nasdaq: HRTX) announced that Barry Quart, CEO, and John Poyhonen, President, will engage in a fireside chat at the 2021 Cantor Virtual Global Healthcare Conference. The event is scheduled for September 27, 2021, at 1:20 pm ET. A live webcast will be accessible via the company's website, with a replay available for 60 days post-event. Heron Therapeutics focuses on developing advanced treatments to meet significant unmet patient needs in acute care and oncology. For further details, visit www.herontx.com.
Heron Therapeutics (HRTX) reported financial results for Q2 and H1 2021, highlighting a net loss of $61 million and $113.6 million, respectively. Net product sales for oncology care amounted to $22.4 million in Q2, slightly down from $22.7 million a year prior. ZYNRELEF, a new product launched in July 2021, saw positive early adoption with 61 unique accounts placing orders. However, the company faces challenges in growth projections due to reduced cancer patient treatments amid the pandemic and increased competition. Cash reserves stand at $257.7 million, reflecting a strategic preparation for product launches.
Heron Therapeutics, Inc. (Nasdaq: HRTX) announced the publication of HOPE Hernia-1 study results for ZYNRELEF in hernia repair surgery. The study demonstrates over 90% of patients discharged without opioid prescriptions and 95% recovering opioid-free, showcasing ZYNRELEF's role in non-opioid multimodal analgesia. ZYNRELEF is an extended-release formulation of bupivacaine and meloxicam, approved for postsurgical analgesia. The findings emphasize ZYNRELEF’s potential to minimize opioid use, pivotal in addressing the opioid crisis.
Heron Therapeutics (HRTX) announced the online publication of a new analysis in the journal Pain Management, evaluating the effectiveness of ZYNRELEF (bupivacaine and meloxicam) in adults 65 years and older after bunionectomy and hernia repair. The analysis revealed that 58% of bunionectomy and 87% of hernia repair patients did not require opioids post-surgery. ZYNRELEF was well tolerated, showing a similar safety profile to bupivacaine, with no serious adverse events related to the medication. This positions ZYNRELEF as a significant improvement over standard opioid treatments.
Heron Therapeutics announced a contract with Apexus for ZYNRELEF under the 340B Drug Pricing Program, aimed at improving access to this FDA-approved medication for postoperative pain management. ZYNRELEF, a dual-acting local anesthetic, was approved on May 12, 2021, and provides pain relief for up to 72 hours, significantly reducing the need for opioids. This partnership seeks to ensure that discounted pricing is available to healthcare providers, helping to combat the opioid crisis. Over 90,000 opioid overdose deaths were reported in the year ending September 2020, underscoring the importance of ZYNRELEF's wide availability.
Heron Therapeutics, Inc. (Nasdaq: HRTX) has announced the commercial launch of ZYNRELEF, a dual-acting local anesthetic, now available through national wholesalers and specialty distributors in the U.S. Approved by the FDA on May 12, 2021, ZYNRELEF provides postoperative pain relief for up to 72 hours following surgeries like bunionectomy and total knee arthroplasty. The product aims to reduce opioid reliance and has shown significant efficacy in pain management. Heron has secured contracts with major purchasing organizations to enhance market penetration.
Heron Therapeutics (Nasdaq: HRTX) announced that CEO Barry Quart will participate in a fireside chat at the 2021 Jefferies Virtual Healthcare Conference on June 1, 2021, at 11:00 AM PT. A live webcast of the event will be available on the company's website and will be archived for 60 days. Heron Therapeutics focuses on developing innovative treatments for unmet patient needs, especially in acute care and oncology.
FAQ
What is the current stock price of Heron Therapeutics (HRTX)?
What is the market cap of Heron Therapeutics (HRTX)?
What products does Heron Therapeutics offer?
What is ZYNRELEF used for?
What recent financial initiatives has Heron Therapeutics undertaken?
What is the Biochronomer™ platform?
What are the recent corporate updates from Heron Therapeutics?
When was ZYNRELEF first approved by the FDA?
What is APONVIE used for?
What steps has Heron taken to achieve profitability?
How does SUSTOL help cancer patients?
Where can I find more information about Heron Therapeutics?
